Biotechnology Acquisitions in New Jersey

Sun Pharmaceutical Industries Limited has completed the acquisition of Checkpoint Therapeutics, Inc., acquiring all outstanding shares for $4.10 per share in cash plus a contingent value right. The deal gives Sun Pharma ownership of UNLOXCYT (cosibelimab-ipdl), the FDA-approved anti-PD-L1 therapy for advanced cutaneous squamous cell carcinoma, and expands its oncology/onco-derm product portfolio.

TenX Keane Acquisition (Nasdaq: TENK) completed a merger with Citius Pharmaceuticals' wholly owned oncology subsidiary to form the publicly traded Citius Oncology, Inc. Citius Pharmaceuticals retains approximately 90% ownership of the new company, which will commercialize the recently FDA-approved oncology therapy LYMPHIR and trade on Nasdaq under the ticker CTOR.

HTL Biotechnology has acquired the beauty and biomedical division of American company Modern Meadow, including its recombinant proteins platform and leading human recombinant collagen type III (rhCOL3) technology. The deal expands HTL's biopolymer portfolio and R&D/manufacturing capabilities, strengthens its presence in North America, and accelerates development of cosmetic and medical-grade recombinant collagen products.

Astellas Pharma has agreed to acquire 100% of IVERIC bio for $40.00 per share, implying an aggregate equity value of roughly $5.9 billion. The acquisition strengthens Astellas' ophthalmology capabilities and adds Iveric's lead program avacincaptad pegol (ACP) for geographic atrophy secondary to AMD to Astellas' pipeline.

Arsenal Capital Partners closed a previously announced $449 million stock purchase in Certara, acquiring shares from funds controlled by EQT Private Equity and becoming a long-term minority investor. As part of the transaction Arsenal appointed Operating Partner David Spaight to Certara's board while Stephen McLean remains a director; Arsenal agreed to a two-year lock-up on the newly purchased shares.

Full‑Life Technologies, a global radiotherapeutics company, agreed to acquire New Jersey‑based Focus‑X Therapeutics to expand its peptide‑focused radiopharmaceutical pipeline. Focus‑X shareholders are eligible for an upfront payment plus up to $245 million in development, regulatory and sales milestones and royalties; the deal was expected to close in Q1 2023.

SFW Capital Partners completed a strategic growth investment in Sannova Analytical, a Somerset, New Jersey-based bioanalytical CRO that provides bioanalytical and CMC testing services to pharmaceutical and biotech companies. Founders and existing owners (including the Marepalli family, Dr. Venkat Reddy, Malleswar Kollu, and Geeta Vidiyala) are reinvesting and retaining an equity stake; SFW will support expansion of services, capacity, and pursue strategic acquisitions to accelerate growth.

BICO has acquired the assets and operations of HUREL Corp., a US-based provider of 2D liver co-culture models and assay services, for approximately USD 2.5 million. The HUREL portfolio and team will be integrated into BICO subsidiary Visikol to expand the group's liver in vitro model and assay offerings for pharma, biotech and academic customers.

Gilead Sciences agreed to acquire Immunomedics for $88.00 per share in an all-cash transaction valuing Immunomedics at approximately $21 billion. The acquisition gives Gilead global rights (outside certain Asian territories) to Trodelvy, an FDA‑approved antibody‑drug conjugate for metastatic triple‑negative breast cancer, and accelerates Gilead’s expansion into oncology.